EGFR and non-small cell lung carcinoma: Thus, selective targeted EGFR tyrosine kinase inhibitors (TKIs) are widely developed and used for the treatment of NSCLC (Hanahan and Weinberg, 2011), which has remarkable therapeutic effects against NSCLC patients with EGFR mutations.